FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains

Stocktwits·Feb 5

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA has determined that a tv advertisement for Novo Nordisk's obesity pill, Wegovy, contains false or misleading claims. This assessment has been communicated to the company, with some reports indicating that the FDA issued an untitled letter. The development has reportedly impacted the company's stock, with gains being pared.

Full coverage

FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims

CNBC·Feb 9

Wegovy: FDA accuses Novo Nordisk of “false or misleading” ad for weight loss pill

The BMJ·Feb 14

FDA untitled letters target Novo’s 1st Wegovy pill ad and spots from argenx, Sobi

Fierce Pharma·Feb 10

FDA cites Novo Nordisk again for misleading GLP-1 ad

RAPS·Mar 5

View original report at Stocktwits ↗

Fetching the latest headlines…

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains

Full coverage

FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims

US FDA says Novo's obesity pill TV ad is false or misleading

Novo’s Obesity Pill TV Ad Includes Misleading Claims, FDA Says

Novo Nordisk slapped with FDA letter for Wegovy oral pill launch ad

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Wegovy: FDA accuses Novo Nordisk of “false or misleading” ad for weight loss pill

FDA untitled letters target Novo’s 1st Wegovy pill ad and spots from argenx, Sobi

FDA cites Novo Nordisk again for misleading GLP-1 ad